• BTB Domain Missense Mutations in ZBTB24 Destabilize Protein

  2026-06-11

  A recent study demonstrates that missense substitutions in the BTB domain of ZBTB24 result in protein instability and underlie the pathogenesis of ICF2 syndrome, a rare disorder characterized by immunodeficiency and genomic hypomethylation. This work expands the spectrum of pathogenic ZBTB24 variants and informs mechanistic understanding relevant to epigenetic regulation and rare disease diagnostics.

• Intestinal TM6SF2 Modulates MASH via Gut–Liver Axis and Micr

  2026-06-11

  This study demonstrates that intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis (MASH) by maintaining gut barrier integrity and modulating host–microbe interactions. The findings highlight how TM6SF2 deficiency in intestinal epithelial cells drives microbial dysbiosis, lipid signaling disturbances, and hepatic inflammation—indicating new therapeutic opportunities targeting the gut–liver axis.

• Dual-Action Kinase Inhibitors Promote Dephosphorylation of p

  2026-06-10

  The referenced study uncovers how certain dual-action kinase inhibitors not only suppress p38α MAPK activity but also accelerate its dephosphorylation by phosphatases. This mechanistic insight opens new avenues for designing inhibitors with improved specificity and efficacy in modulating inflammatory signaling.

• Epigenetic Suppression of Mcl-1 Enhances Bcl-2 Inhibition in

  2026-06-10

  This study demonstrates that targeting the Mcl-1 super-enhancer with THZ1 sensitizes glioblastoma cells to Bcl-2/Bcl-xL inhibition, leading to synergistic apoptosis via the mitochondrial pathway. The findings propose a rationale for combining epigenetic and BH3-mimetic strategies to overcome apoptotic resistance in glioblastoma.

• CA-074 Me (Cathepsin B inhibitor): Reliable Tools for Lysoso

  2026-06-09

  This article addresses challenges in cell viability and lysosomal enzyme assays, illustrating how CA-074 Me (Cathepsin B inhibitor, SKU A8239) streamlines cathepsin B inhibition with high selectivity and reproducibility. Scenario-driven Q&A blocks translate recent mechanistic findings and best practices into actionable laboratory guidance for biomedical researchers.

• Resiniferatoxin (RTX): Immunomodulatory Insights and Analges

  2026-06-09

  Explore how Resiniferatoxin (RTX), an ultra-potent TRPV1 agonist, delivers precise sensory neuron desensitization and reveals new immunomodulatory dimensions in pain research. Discover unique protocol parameters, clinical relevance, and recent evidence linking TRPV1 modulation to immune system outcomes.

• Resiniferatoxin (RTX): Precision Tools for TRPV1 Pain Resear

  2026-06-08

  This in-depth article addresses real laboratory pain points in TRPV1 assay reproducibility, protocol optimization, and product selection using Resiniferatoxin (RTX, SKU BA7012). Scientists will find scenario-driven guidance, literature-backed recommendations, and actionable links to best practices for deploying RTX in pain and inflammation research.

• Applied Workflows with G-1, a Selective GPR30 Agonist: Proto

  2026-06-08

  G-1 (CAS 881639-98-1) empowers precise dissection of GPR30 signaling in cardiovascular and oncology models, offering unmatched selectivity over classical estrogen receptors. This guide details stepwise protocols, advanced applications, and troubleshooting insights—grounded in recent mechanistic discoveries and direct comparative evidence.

• Anlotinib Hydrochloride: Multi-Target TKI for Angiogenesis A

  2026-06-07

  Anlotinib hydrochloride stands out as a next-generation multi-target tyrosine kinase inhibitor, delivering superior anti-angiogenic efficacy in functional endothelial assays and tumor models. This guide translates cutting-edge research into actionable protocols, troubleshooting strategies, and comparative insights for advanced cancer research workflows.

• Resiniferatoxin (RTX): Advanced Workflows in Pain Research

  2026-06-06

  Resiniferatoxin (RTX) empowers researchers to dissect and silence pain signaling with unmatched selectivity for TRPV1-positive neurons. Leveraging its ultra-potent action and robust protocol guidance, RTX enables reproducible modeling of neuropathic and osteoarthritis pain, setting new standards for translational analgesia research.

• Mc-Val-Cit-PABC-PNP: Technical Guide for ADC Peptide Linker

  2026-06-05

  Mc-Val-Cit-PABC-PNP is a cathepsin B-cleavable ADC peptide linker designed to enable efficient and selective payload release in antibody-drug conjugate (ADC) workflows. It is recommended for research applications requiring lysosomal cleavage specificity and is not suitable for water-based protocols, diagnostic, or medical use.

• Oligomycin A: Mitochondrial ATP Synthase Inhibitor in Cancer

  2026-06-05

  Oligomycin A, a gold-standard mitochondrial ATP synthase inhibitor, empowers researchers to dissect metabolic adaptation and apoptosis pathways with unrivaled precision. By integrating insights from recent mitochondrial metabolism studies and validated workflows, this guide delivers actionable protocols and troubleshooting strategies for robust bioenergetics and cancer metabolism research.

• JNJ-26854165 (Serdemetan): Advanced Insights for p53-Targete

  2026-06-04

  Explore how JNJ-26854165 (Serdemetan) enables precise p53 pathway modulation in cancer research, focusing on nuanced cellular responses and assay optimization. This article uniquely bridges mechanistic detail with practical laboratory strategies for superior experimental outcomes.

• Mitochondrial Transfer and ER Remodeling in Orofacial Pain R

  2026-06-04

  Li et al. (2026) identify a neuroprotective mechanism in orofacial inflammatory pain: satellite glial cells transfer mitochondria to trigeminal neurons, restoring mitophagy and calcium balance through ER membrane remodeling. This work clarifies the cellular basis of pain hypersensitivity and highlights mitochondrial-ER dynamics as promising therapeutic targets.

• PRDX6-GPX4 Axis Regulates Ferroptosis and Tumor Resistance M

  2026-06-03

  Hu et al. (2025) uncover how PRDX6 modulates GPX4 localization and function to repair lipid peroxidation, conferring resistance to ferroptosis in tumor cells. Inhibiting PRDX6 disrupts this defense, sensitizing cancers to ferroptosis and offering a promising strategy for overcoming therapeutic resistance.

16281 records 1/1086 page Next 12345 下5页 Last page